AbbVie (ABBV) Net Income - Minority (2020 - 2021)
AbbVie (ABBV) posted quarterly Net Income - Minority of -$25.0 million for Q2 2021, down 4.17% YoY from -$26.1 million in Q2 2020, and down 8.7% sequentially from -$23.0 million in Q1 2021.
AbbVie (ABBV) Net Income - Minority (2020 - 2021) Analysis & Trends
AbbVie has disclosed Net Income - Minority across 2 years of filings, most recently posting -$25.0 million for Q2 2021.
- In Q2 2021, Net Income - Minority fell 4.17% year-over-year to -$25.0 million; the TTM figure through Jun 2021 stood at -$25.0 million (down 4.17% YoY), while the FY2020 annual figure was -$21.0 million, changed N/A from the prior year.
- Net Income - Minority declined to -$25.0 million in Q2 2021, from -$23.0 million in the prior quarter.
- Over the last five years, Net Income - Minority for ABBV reached as high as -$19.0 million in Q3 2020 and fell as low as -$25.0 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -25.00 Mn |
| Mar 31, 2021 | -23.00 Mn |
| Dec 31, 2020 | -21.00 Mn |
| Sep 30, 2020 | -19.00 Mn |
| Jun 30, 2020 | -24.00 Mn |